Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Allogeneic stem cell transplantation as treatment for myelofibrosis

Bone Marrow Transplantation volume 38, pages 721–727 (2006)Cite this article

Abstract

Idiopathic myelofibrosis (IMF) is a clonal disorder resulting from the proliferation of aberrant hematopoietic stem cells. Conventional treatment is unsatisfactory, and with the exception of supportive blood transfusions, none of the standard therapies have been shown to confer a survival advantage. Allogeneic stem cell transplantation represents the only treatment modality with proven curative potential. Myeloablative conditioning regimens are associated with high transplant-related mortality, particularly in the elderly, making most patients with IMF ineligible for this treatment. Strategies using reduced intensity conditioning regimes have allowed application of allogeneic transplantation to a broader range of patients and a number of recent reports have demonstrated potential efficacy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Barosi G . Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 1999; 17: 2954–2970.

    Article  CAS  PubMed  Google Scholar 

  2. Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A . Population based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted Country Study, 1975–1995. Am J Hematol 1999; 61: 10–15.

    Article  CAS  PubMed  Google Scholar 

  3. Cervantes F, Barosi G, Demory JL, Reilly J, Guarnone R, Dupriez B et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol 1998; 102: 684–690.

    Article  CAS  PubMed  Google Scholar 

  4. Tefferi A . Myelofibrosis with myeloid metaplasia. N Engl J Med 2000; 342: 1255–1265.

    Article  CAS  PubMed  Google Scholar 

  5. Navone R, Colombano MT . Histopathological trephine biopsy findings in cases of ‘dry tap’ bone marrow aspiration. Appl Pathol 1984; 2: 264–271.

    CAS  PubMed  Google Scholar 

  6. Cervantes F, Pereira A, Esteve J, Rafel M, Cobo F, Rozman C et al. Identification of ‘long-lived’ and ‘short-lived’ patients at presentation of primary myelofibrosis. Br J Haematol 1997; 97: 635–640.

    Article  CAS  PubMed  Google Scholar 

  7. Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88: 1013–1018.

    CAS  PubMed  Google Scholar 

  8. Cervantes F, Hernandez-Boluda JC, Alvarez A, Nadal E, Montserat E . Danazol treatment of idiopathic myelofibrosis with severe anemia. Haematologica 2000; 85: 595–599.

    CAS  PubMed  Google Scholar 

  9. Cervantez F, Alvarez-Larran A, Hernandez-Boluda JC, Sureda A, Torebadell M, Montserrat E . Erythropoietin treatment of the anemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol 2004; 127: 399–403.

    Article  Google Scholar 

  10. Marchetti M, Barosi G, Balestri F, Viarengo G, Gentili S, Barulli S et al. Low dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. J Clin Oncol 2004; 22: 424–431.

    Article  CAS  PubMed  Google Scholar 

  11. Mesa RA, Steensma DP, Pardanani A, Li CY, Elliott M, Kaufmann SH et al. A phase II trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003; 101: 2534–2541.

    Article  CAS  PubMed  Google Scholar 

  12. Gilbert HS . Long-term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy. Cancer 1998; 83: 1205–1213.

    Article  CAS  PubMed  Google Scholar 

  13. Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein NM . Splenectomy in myelofibrosis with myeloid metaplasia: a single institution experience with 223 patients. Blood 2000; 95: 2226–2233.

    CAS  PubMed  Google Scholar 

  14. Mesa RA, Tefferi A . Surgical and radiotherapeutic approaches for myelofibrosis with myeloid metaplasia. Sem Oncol 2005; 32: 403–413.

    Article  Google Scholar 

  15. Barosi G, Ambrosetti A, Centra A, Falcone A, Finelli C, Foa P et al. Splenectomy risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on myelofibrosis with myeloid metaplasia. Blood 1998; 91: 3630–3636.

    CAS  PubMed  Google Scholar 

  16. Rajantie J, Sale GE, Deeg HJ, Amos F, Appelbaum F, Storb R et al. Adverse effect of severe marrow fibrosis on hematologic recovery after chemoradiotherapy and allogeneic bone marrow transplantation. Blood 1986; 67: 1693–1697.

    CAS  PubMed  Google Scholar 

  17. Soll E, Massumoto C, Clift RA, Buckner CD, Appelbaum FR, Storb R et al. Relevance of marrow fibrosis in bone marrow transplantation: a retrospective analysis of engraftment. Blood 1995; 86: 4667–4673.

    CAS  PubMed  Google Scholar 

  18. Dokal I, Jones L, Deenmamode M, Lewis SM, Goldman JM . Allogeneic bone marrow transplantation for primary myelofibrosis. Br J Haematol 1989; 71: 158–160.

    Article  CAS  PubMed  Google Scholar 

  19. Creemers GJ, Lowenberg B, Hagenbeek A . Allogeneic bone marrow transplantation for primary myelofibrosis. Br J Haematol 1992; 82: 772–773.

    Article  CAS  PubMed  Google Scholar 

  20. Singhal S, Powels R, Treleaven J, Pollard C, Lumley H, Metha J . Allogeneic bone marrow transplantation for primary myelofibrosis. Bone Marrow Transplantation 1995; 16: 743–746.

    CAS  PubMed  Google Scholar 

  21. Anderson JE, Sale G, Appelbaum FR, Chauncey TR, Storb R . Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis. Br J Haematol 1997; 98: 1010–1016.

    Article  CAS  PubMed  Google Scholar 

  22. Guardiola P, Esperou H, Cazals-Hatem D, Ifrah N, Jouet JP, Buzyn A et al. Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia: French Society of Bone Marrow Transplantation. Br J Haematol 1997; 98: 1004–1009.

    Article  CAS  PubMed  Google Scholar 

  23. Guardiola P, Anderson J, Bandini G, Cervantes F, Runde V, Arcese W et al. Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia: A European group for blood and marrow transplantation, societe Francaise de Greffe de Moelle, Groupo Italiano per il Trapiano del Midollo Osseo, and Fred Hutchinson cancer research center collaborative study. Blood 1999; 93: 2831–2838.

    CAS  PubMed  Google Scholar 

  24. Deeg HJ, Gooley T, Flowers M, Sale G, Slattery J, Anasetti C et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003; 102: 3912–3918.

    Article  CAS  PubMed  Google Scholar 

  25. Daly A, Song K, Nevill T, Nantel S, Toze C, Hogge D et al. Stem cell transplantation for myelofibrosis: a report from two Canadian centers. Bone Marrow Transplant 2003; 32: 35–40.

    Article  CAS  PubMed  Google Scholar 

  26. Ditschkowski M, Beelen DW, Trenschel R, Koldehoff M, Elmaagacli AH . Outcome of allogeneic stem cell transplantation in patients with myelofibrosis. Bone Marrow Transplant 2004; 34: 807–813.

    Article  CAS  PubMed  Google Scholar 

  27. Przepiorka D, Giralt S, Khouri I, Champlin R, Bueso-Ramos C . Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases. Am J Hematol 1998; 57: 24–28.

    Article  CAS  PubMed  Google Scholar 

  28. Mittal P, Saliba RM, Giralt SA, Shahjahan M, Cohen AI, Karandish S et al. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia. Bone Marrow Transplant 2004; 33: 1005–1009.

    Article  CAS  PubMed  Google Scholar 

  29. Guardiola P, Anderson J, Gluckman E . Myelofibrosis with myeloid metaplasia [letter]. N Engl J Med 2000; 343: 659.

    Article  CAS  PubMed  Google Scholar 

  30. Benesch M, Deeg HJ . Hematopoietic cell transplantation for adults patients with myelodysplastic syndromes and myeloproliferative disorders. Mayo Clin Proc 2003; 78: 981–990.

    Article  PubMed  Google Scholar 

  31. Mariarz RT, Mesa RA, Tefferi A . Allogeneic stem cell transplantation for chronic myeloproliferative disorders and myelodysplastic syndromes: the question is ‘when?’. Mayo Clin Proc 2003; 78: 941–943.

    Article  Google Scholar 

  32. Byrne JL, Beshti H, Clark D, Ellis I, Haynes AP, Das-Gupta E et al. Induction of remission after donor leukocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: evidence for a ‘graft vs myelofibrosis’ effect. Br J Haematol 2000; 108: 430–433.

    Article  CAS  PubMed  Google Scholar 

  33. Cervantes F, Rovira M, Urbano-Ispizua A, Rozman M, Carreras E, Montserrat E . Remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic stem cell transplantation. Bone Marrow Transplant 2000; 26: 697–699.

    Article  CAS  PubMed  Google Scholar 

  34. Devine SM, Hoffman R, Verma A, Shah R, Bradlow BA, Stock W et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 2002; 99: 2255–2258.

    Article  CAS  PubMed  Google Scholar 

  35. Hessling J, Kroger N, Werner M, Zabelina T, Hansen A, Kordes U et al. Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2002; 119: 769–772.

    Article  PubMed  Google Scholar 

  36. Tanner ML, Hoh CK, Bashey A, Holman P, Sun C, Broome HE et al. FLAG chemotherapy followed by allogeneic stem cell transplant using nonmyeloablative conditioning induces regression of myelofibrosis with myeloid metaplasia. Bone Marrow Transplant 2003; 32: 581–585.

    Article  CAS  PubMed  Google Scholar 

  37. Greyz N, Miller WE, Andrey J, Mason J . Long term remission of myelofibrosis following nonmyeloablative allogeneic peripheral blood progenitor cell transplantation in older age: the Scipps Clinic experience. Bone Marrow Transplant 2004; 34: 273–274.

    Article  CAS  PubMed  Google Scholar 

  38. van Besien K, Deeg HJ . Hematopoietic stem cell transplantation for myelofibrosis. Sem Oncol 2005; 32: 414–421.

    Article  Google Scholar 

  39. Rondelli D, Barosi G, Bacigalupo A, Prchal J, Popat U, Alessandrino E et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 2005; 105: 4115–4119.

    Article  CAS  PubMed  Google Scholar 

  40. Kroger N, Zabelina T, Schieder H, Panse J, Ayuk F, Stute N et al. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelofibrosis. Br J Haematol 2005; 128: 690–697.

    Article  PubMed  Google Scholar 

  41. Cutler CS, Lee SJ, Greenberg P, Deeg J, Pérez WS, Anasetti C et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004; 104: 579–585.

    Article  CAS  PubMed  Google Scholar 

  42. Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G et al. Allogeneic stem-cell transplantation using a reduced intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005; 23: 9387–9393.

    Article  CAS  PubMed  Google Scholar 

  43. Martino R, Iacobelli S, Brand R, Jansen T, van Biezen A, Finke J et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic haematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006; 108: 836–846.

    Article  CAS  PubMed  Google Scholar 

  44. Tefferi A, Deeg HJ . Deciding on transplantation for myelofibrosis: setting the record straight. Mayo Clin Proc 2004; 79: 953–954.

    Article  PubMed  Google Scholar 

  45. Dingli D, Schwager SM, Mesa RA, Li CY, Tefferi A . Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia. Cancer 2006; 106: 623–630.

    Article  PubMed  Google Scholar 

  46. Tefferi A, Dingli D, Li CY, Dewald GW . Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia. Cancer 2005; 104: 1656–1660.

    Article  CAS  PubMed  Google Scholar 

  47. de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic haemopoietic stem cell transplantation. Blood 2004; 104: 865–872.

    Article  CAS  PubMed  Google Scholar 

  48. Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000; 96: 2419–2425.

    CAS  PubMed  Google Scholar 

  49. Mohty M, Bay JO, Faucher C, Choufi B, Bilger K, Tournilhac O et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with anti-thymocyte globulin-based reduced-intensity preparative regimen. Blood 2003; 102: 470–476.

    Article  CAS  PubMed  Google Scholar 

  50. Chakraberti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, O'Gorman P et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: a potential role of Campath-1H in delaying immune reconstitution. Blood 2002; 99: 4357–4363.

    Article  Google Scholar 

  51. Mohty M, Jacot W, Faucher C, Bay JO, Zandotti C, Collet L et al. Infectious complications following allogeneic HLA-identical sibling transplantation with anti-thymocyte globulin-based reduced intensity preparative regimen. Leukemia 2003; 17: 2168–2177.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, Royal Free and University College London Medical School, London, UK

    S G Papageorgiou, A Castleton & P D Kottaridis

  2. Second Department of Internal Medicine, Propaedeutic, Medical School, University of Athens, University General Hospital ‘Attikon’, Haidari, Greece

    S G Papageorgiou

  3. Department of Haematology, Christie Hospital NHS Trust, Manchester, UK

    A Bloor

Authors
  1. S G Papageorgiou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Castleton
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Bloor
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P D Kottaridis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P D Kottaridis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Papageorgiou, S., Castleton, A., Bloor, A. et al. Allogeneic stem cell transplantation as treatment for myelofibrosis. Bone Marrow Transplant 38, 721–727 (2006). https://doi.org/10.1038/sj.bmt.1705516

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705516

Keywords

This article is cited by

Search

Advanced search

Quick links